COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics
CMPS Price/Volume Stats
| Current price | $6.87 | 52-week high | $11.91 |
| Prev. close | $7.40 | 52-week low | $6.79 |
| Day low | $6.79 | Volume | 924,421 |
| Day high | $7.58 | Avg. volume | 327,757 |
| 50-day MA | $8.68 | Dividend yield | N/A |
| 200-day MA | $8.84 | Market Cap | 314.37M |
CMPS Stock Price Chart Interactive Chart >
COMPASS Pathways PLC ADR (CMPS) Company Bio
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Latest CMPS News From Around the Web
Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.
Don’t Miss the Boom: 3 Psychedelic Stocks Set to Explode HigherDespite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions. |
COMPASS Pathways appoints Daphne Karydas to its Board of DirectorsLONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for c |
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depressionLONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The paper was published on |
COMPASS Pathways to participate in upcoming September investor conferencesLONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences: Citi’s 18th Annual BioPharma Conference: host investor meetings on September 7, 2023HC Wainwright 25th Annual Global Investment Conference: fireside chat at 3:30pm on September 11, 2023 and host investor meetingsMorgan St |
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall StreetCathie Wood is one of the most influential investors in the world. ARK Invest manages several exchange-traded funds (ETFs) that have delivered stellar returns for investors in 2023. Beam Therapeutics (NASDAQ: BEAM), COMPASS Pathways (NASDAQ: CMPS), and 908 Devices (NASDAQ: MASS) are three ARK Invest holdings with strong buy ratings and exceptionally high price targets from the analysts who cover them. |
CMPS Price Returns
| 1-mo | -26.37% |
| 3-mo | N/A |
| 6-mo | -31.51% |
| 1-year | -35.97% |
| 3-year | -81.34% |
| 5-year | N/A |
| YTD | -14.45% |
| 2022 | -63.67% |
| 2021 | -53.61% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...